PMOS is linked to early gestational diabetes and poorer neonatal outcomes

Design

Prospective cohort nested within a multicentre RCT

Population

3,645 pregnant women with risk factors for hyperglycaemia

Primary outcome

Early gestational diabetes and adverse maternal and neonatal outcomes by PMOS status

Effect

Early GDM aOR 1.37 (95% CI 1.10–1.72); composite neonatal aOR 1.28 (1.04–1.58)

Polyendocrine metabolic ovarian syndrome (PMOS) is the new name for polycystic ovary syndrome. This nested prospective cohort drew on 3,645 pregnant women with risk factors for hyperglycaemia enrolled in an international randomised trial of early gestational diabetes treatment. PMOS prevalence was 17.1%.

After adjustment for age, BMI, ethnicity, parity, smoking and education, PMOS was associated with early gestational diabetes (aOR 1.37, 95% CI 1.10–1.72), a composite of adverse neonatal outcomes (aOR 1.28, 1.04–1.58) and neonatal unit admission (aOR 1.32, 1.05–1.65). Babies were born about 1.6 days earlier and 0.33 cm shorter. The associations did not vary by BMI or ethnicity.

The practical point is that PMOS is an independent pregnancy risk marker, not just a proxy for weight. It belongs on the list of reasons to test glucose early in pregnancy.

• Ask about PMOS (PCOS) at the booking visit and record it as a risk factor.
• Offer early glucose testing in women with PMOS rather than waiting for 24–28 weeks.
• The risk held regardless of BMI — lean women with PMOS are not exempt.
• Tell the obstetric team: PMOS was associated with more neonatal unit admissions.
• Use preconception visits to optimise weight and glycaemia in women with PMOS planning pregnancy.

Why it matters

It moves PMOS from a fertility diagnosis to a pregnancy risk factor that should change screening timing.

Don't overread it

This was an observational cohort of already high-risk women — it shows association, not that treating PMOS changes outcomes.

The statistics, in plain English

An adjusted odds ratio of 1.37 means about 37% higher odds of early gestational diabetes after accounting for the listed factors. The confidence interval (1.10–1.72) does not cross 1.0, so the association is unlikely to be chance. The neonatal differences in days and centimetres are small individually; the composite outcome and unit admissions are the clinically meaningful ones.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.